In Singulo Solutions AB was founded in October 2017 following a five year collaboration of Chalmers Tekniska Högskola and AstraZeneca. In Singulo Solutions next generation of biosensing platform overcomes the limitations of current biosensing methods and advances the drug discovery and development process by delivering more relevant data significantly faster. The proprietary and awarded technology of In Singulo Solutions has already proven its advantages in developing drugs targeting the important membrane proteins. In Singulo Solutions technology has the potential to fundamentally impact the way drugs are developed. With lowered cost, higher precision and more relevant data it will allow to target diseases that are not targeted today.
Investors 1
| Date | Name | Website |
| - | Chalmers V... | chalmersve... |